REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

REGENXBIO Inc.

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on RegenXBio today and set a price target of $34.00. The company’s shares opened today at $...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RGNX	$11.80	+8.56%	453.20K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RGNX	$11.80	+8.6%	453.20K
3
4
5
6

RGNX

RGNX

No Data Available

Get REGENXBIO Inc. Data in Excel

Get REGENXBIO Inc. Data in Excel